F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients

Nuclear Medicine Communications

Volumn 28, Issue 11, 2007, Pages 834-841

  Karantanis, Dimitrios ^a   O'Neill, Brian P ^a   Subramaniam, Rathan M ^a   Witte, Robert J ^a   Mullan, Brian P ^b   Nathan, Mark A ^b   Lowe, Val J ^b   Peller, Patrick J ^c   Wiseman, Gregory A ^c  

^a Division of Nuclear Medicine   (United States)

^b Department of Neurology ^*  (United States)

^c MAYO CLINIC   (United States)

Author keywords

PCNSL; Primary CNS lymphoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DIAGNOSTIC AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; RITUXIMAB;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPINAL CORD; TUMOR BIOPSY; TUMOR LOCALIZATION; CENTRAL NERVOUS SYSTEM TUMOR; COHORT ANALYSIS; MIDDLE AGED; NONHODGKIN LYMPHOMA; SCINTISCANNING; SERODIAGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HIV SERONEGATIVITY; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 34848850794     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328264ae7f     Document Type: Article

References (22)

1. Central Brain Tumor Registry of the United States. 1995-1999 data. 2002. Available from URL: [Accessed 20 February 2007].
2. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988; 68:835-853.
3. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 1994; 74:1383-1397.
4. Maher EA, Fine HA. Primary CNS lymphoma. Semin Oncol 1999; 26:346-356.
5. Krogh-Jensen M, D'Amore F, Jensen MK, Christensen BE, Thorling K, Pedersen M, et al. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry. Leuk Lymphoma 1995; 19:223-233.
6. Loeffler JS, Ervin TJ, Mauch P, Skarin A, Weinstein HJ, Canellos G, Cassady JR. Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol 1985; 3:490-494.
7. Ferreri AJ, Reni M, Zoldan MC, Terreni MR, Villa E. Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. Cancer 1996; 77:827-833.
8. O'Neill BP, Illig JJ. Primary central nervous system lymphoma. Mayo Clin Proc 1989; 64:1005-1020.
9. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203:795-800.
10. Schoder H, Meta J, Yap C, Ariannejad M, Rao J, Phelps ME, et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001; 42:1139-1143.
11. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16:603-609.
12. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma - comparison with CT. Leuk Lymphoma 2000; 39:543-553.
13. 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055-1063.
14. Zinzani PL, Fanti S, Battista G, Tani M, Castellucci P, Stefoni V, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004; 91:850-854.
15. 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005; 11:7146s-7150s.
16. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43:1018-1027.
17. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16:1514-1523.
18. Karantanis D, O'Neil BP, Subramaniam RM, Peller PJ, Witte RJ, Mullan BP, Wiseman GA. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. Clin Nucl Med 2007; 32:271-274.
19. 18F]FDG uptake in primary cerebral lymphoma: a PET study. J Comput Assist Tomogr 1988; 12:47-48.
20. Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992; 33:532-536.
21. Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006; 33:164-168.
22. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, Ohkawa M. Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging 2006; 34:78-86.